|
1
|
Stefanovic F, Martinez JA, Saleem GT, Sisto SA, Miller MT, Achampong YA, Titus AH. A blended neurostimulation protocol to delineate cortico-muscular and spino-muscular dynamics following neuroplastic adaptation. Front Neurol 2023; 14:1114860. [PMID: 37396760 PMCID: PMC10311503 DOI: 10.3389/fneur.2023.1114860] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2022] [Accepted: 06/02/2023] [Indexed: 07/04/2023] Open
Abstract
In this paper we propose a novel neurostimulation protocol that provides an intervention-based assessment to distinguish the contributions of different motor control networks in the cortico-spinal system. Specifically, we use a combination of non-invasive brain stimulation and neuromuscular stimulation to probe neuromuscular system behavior with targeted impulse-response system identification. In this protocol, we use an in-house developed human-machine interface (HMI) for an isotonic wrist movement task, where the user controls a cursor on-screen. During the task, we generate unique motor evoked potentials based on triggered cortical or spinal level perturbations. Externally applied brain-level perturbations are triggered through TMS to cause wrist flexion/extension during the volitional task. The resultant contraction output and related reflex responses are measured by the HMI. These movements also include neuromodulation in the excitability of the brain-muscle pathway via transcranial direct current stimulation. Colloquially, spinal-level perturbations are triggered through skin-surface neuromuscular stimulation of the wrist muscles. The resultant brain-muscle and spinal-muscle pathways perturbed by the TMS and NMES, respectively, demonstrate temporal and spatial differences as manifested through the human-machine interface. This then provides a template to measure the specific neural outcomes of the movement tasks, and in decoding differences in the contribution of cortical- (long-latency) and spinal-level (short-latency) motor control. This protocol is part of the development of a diagnostic tool that can be used to better understand how interaction between cortical and spinal motor centers changes with learning, or injury such as that experienced following stroke.
Collapse
Affiliation(s)
- Filip Stefanovic
- Department of Biomedical Engineering, State University of New York at Buffalo, Buffalo, NY, United States
| | - Julian A. Martinez
- Department of Biomedical Engineering, State University of New York at Buffalo, Buffalo, NY, United States
| | - Ghazala T. Saleem
- Department of Rehabilitation Science, State University of New York at Buffalo, Buffalo, NY, United States
| | - Sue Ann Sisto
- Department of Rehabilitation Science, State University of New York at Buffalo, Buffalo, NY, United States
| | - Michael T. Miller
- UB Department of Biomedical Engineering, State University of New York at Buffalo, Buffalo, NY, United States
| | - Yaa A. Achampong
- UB Department of Biomedical Engineering, State University of New York at Buffalo, Buffalo, NY, United States
| | - Albert H. Titus
- Department of Biomedical Engineering, State University of New York at Buffalo, Buffalo, NY, United States
| |
Collapse
|
|
2
|
Low-Frequency Repetitive Transcranial Magnetic Stimulation for Stroke-Induced Upper Limb Motor Deficit: A Meta-Analysis. Neural Plast 2017; 2017:2758097. [PMID: 29435371 PMCID: PMC5756908 DOI: 10.1155/2017/2758097] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2017] [Accepted: 10/01/2017] [Indexed: 11/21/2022] Open
Abstract
Background and Purpose This meta-analysis aimed to evaluate the therapeutic potential of low-frequency repetitive transcranial magnetic stimulation (LF-rTMS) over the contralesional hemisphere on upper limb motor recovery and cortex plasticity after stroke. Methods Databases of PubMed, Medline, ScienceDirect, Cochrane, and Embase were searched for randomized controlled trials published before Jun 31, 2017. The effect size was evaluated by using the standardized mean difference (SMD) and a 95% confidence interval (CI). Resting motor threshold (rMT) and motor-evoked potential (MEP) were also examined. Results Twenty-two studies of 1 Hz LF-rTMS over the contralesional hemisphere were included. Significant efficacy was found on finger flexibility (SMD = 0.75), hand strength (SMD = 0.49), and activity dexterity (SMD = 0.32), but not on body function (SMD = 0.29). The positive changes of rMT (SMD = 0.38 for the affected hemisphere and SMD = −0.83 for the unaffected hemisphere) and MEP (SMD = −1.00 for the affected hemisphere and SMD = 0.57 for the unaffected hemisphere) were also significant. Conclusions LF-rTMS as an add-on therapy significantly improved upper limb functional recovery especially the hand after stroke, probably through rebalanced cortical excitability of both hemispheres. Future studies should determine if LF-rTMS alone or in conjunction with practice/training would be more effective. Clinical Trial Registration Information This trial is registered with unique identifier CRD42016042181.
Collapse
|
|
3
|
Kobayashi B, Cook IA, Hunter AM, Minzenberg MJ, Krantz DE, Leuchter AF. Can neurophysiologic measures serve as biomarkers for the efficacy of repetitive transcranial magnetic stimulation treatment of major depressive disorder? Int Rev Psychiatry 2017; 29:98-114. [PMID: 28362541 DOI: 10.1080/09540261.2017.1297697] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Repetitive transcranial magnetic stimulation (rTMS) is an effective treatment for Major Depressive Disorder (MDD). There are clinical data that support the efficacy of many different approaches to rTMS treatment, and it remains unclear what combination of stimulation parameters is optimal to relieve depressive symptoms. Because of the costs and complexity of studies that would be necessary to explore and compare the large number of combinations of rTMS treatment parameters, it would be useful to establish reliable surrogate biomarkers of treatment efficacy that could be used to compare different approaches to treatment. This study reviews the evidence that neurophysiologic measures of cortical excitability could be used as biomarkers for screening different rTMS treatment paradigms. It examines evidence that: (1) changes in excitability are related to the mechanism of action of rTMS; (2) rTMS has consistent effects on measures of excitability that could constitute reliable biomarkers; and (3) changes in excitability are related to the outcomes of rTMS treatment of MDD. An increasing body of evidence indicates that these neurophysiologic measures have the potential to serve as reliable biomarkers for screening different approaches to rTMS treatment of MDD.
Collapse
Affiliation(s)
- Brian Kobayashi
- a David Geffen School of Medicine , University of California Los Angeles , Los Angeles , CA , USA.,b Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine , University of California Los Angeles , Los Angeles , CA , USA.,c Neuromodulation Division , Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles , Los Angeles , CA , USA
| | - Ian A Cook
- a David Geffen School of Medicine , University of California Los Angeles , Los Angeles , CA , USA.,b Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine , University of California Los Angeles , Los Angeles , CA , USA.,c Neuromodulation Division , Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles , Los Angeles , CA , USA.,d Department of Bioengineering , University of California Los Angeles , Los Angeles , CA , USA
| | - Aimee M Hunter
- a David Geffen School of Medicine , University of California Los Angeles , Los Angeles , CA , USA.,b Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine , University of California Los Angeles , Los Angeles , CA , USA.,c Neuromodulation Division , Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles , Los Angeles , CA , USA
| | - Michael J Minzenberg
- a David Geffen School of Medicine , University of California Los Angeles , Los Angeles , CA , USA.,b Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine , University of California Los Angeles , Los Angeles , CA , USA.,c Neuromodulation Division , Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles , Los Angeles , CA , USA
| | - David E Krantz
- a David Geffen School of Medicine , University of California Los Angeles , Los Angeles , CA , USA.,b Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine , University of California Los Angeles , Los Angeles , CA , USA.,c Neuromodulation Division , Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles , Los Angeles , CA , USA
| | - Andrew F Leuchter
- a David Geffen School of Medicine , University of California Los Angeles , Los Angeles , CA , USA.,b Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine , University of California Los Angeles , Los Angeles , CA , USA.,c Neuromodulation Division , Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles , Los Angeles , CA , USA
| |
Collapse
|